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ABSTRACT 
Primary hyperparathyroidism (pHPT) is associated with increased mortality in certain 
malignant tumours. Breast cancer is the most common and a shared aetiology has been 
suggested. In a register-based nested case-control study, we compared breast cancer in 
patients with and without a previous operation for pHPT. Neither tumour size or stage, 
nor lymph node metastases differed, nor did breast cancer specific survival. 
 
Longer life expectancy and a lower threshold for referral of pHPT patients to surgery 
have lead to an increasing proportion of elderly patients. In a large cohort study of the 
period 1961-2004, all-cause mortality within 30 days and one year after surgery for 
pHPT was analysed. The entire Swedish population, standardized for age, sex and time 
period, served as control. During the study period, 30-day mortality decreased from 
4.2% to 0.4% and mean age increased by 11 years (53-64 years). Cardiovascular 
disease was the dominant cause of death in both sexes and all age groups. 
 
Patients with pHPT have lower bone mineral density and display several risk factors of 
cardiovascular disease. Vitamin D deficiency is more common in pHPT and could 
aggravate the complications. In a randomized clinical trial, we examined the effect of 
vitamin D supplementation on bone mineral density, blood pressure and metabolic risk 
factors after curative surgery for pHPT. 150 patients were randomized to either calcium 
and vitamin D or calcium alone. Surgery had a positive effect on bone mineral density 
and insulin resistance and a small positive effect on systolic blood pressure. There was 
no obvious additive effect of vitamin D supplementation. 
 
Conclusions: Breast cancer in pHPT patients seems to have the same characteristics 
and prognosis as in the general population. Parathyroidectomy is a safe operation, even 
in the elderly, and leads to improvements in bone mineral density, insulin resistance 
and to a lesser extent in systolic blood pressure. Vitamin D supplementation after 
surgical cure had no obvious beneficial effect. 
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1 INTRODUCTION 
1.1 PRIMARY HYPERPARATHYROIDISM  
1.1.1 Clinical presentation of primary hyperparathyroidism 
Primary hyperparathyroidism (pHPT) is a common endocrine disorder, characterized 
by elevated or “high normal” serum calcium in combination with an inappropriately 
high level of parathyroid hormone (PTH). It is caused by excessive, incompletely 
regulated secretion of PTH from one or more of the parathyroid glands. In more than 
80% of the cases there is a single, benign parathyroid adenoma: in the remaining cases, 
multiglandular involvement is seen. Parathyroid cancer is rare (0.5% of the cases)1.  
PHPT is mostly a sporadic disease, but a small percentage of the cases is part of a 
hereditary multiple endocrine neoplasia type I or IIa, HPT-jaw tumour syndrome or 
other rare hereditary disorders2. The introduction of automated serum analyses of 
calcium in the early 1970s, led to a sharp increase in the observed prevalence of pHPT. 
Today the prevalence is around 1%, with a female:male ratio of 3:13-7. It increases with 
age in both sexes, with a prevalence up to 3.4% or even higher, in postmenopausal 
women3,5,8,9. In a Swedish screening study on premenopausal women, the prevalence of 
assumed mild pHPT was as high as 5.1%, and 2.7% on repeated measures10. 
  
Besides the increased prevalence, the clinical picture has changed from the classic 
symptoms of severe osteoporosis or osteitis fibrosa cystica, gastrointestinal symptoms, 
muscle weakness, psychiatric symptoms, kidney stones and nephrocalcinosis2 to a more 
or less asymptomatic disease in a majority of the patients11. By definition, 
asymptomatic pHPT presents without overt clinical signs. However, these patients 
often have reduced bone mineral density (BMD), preferentially in cortical bone12-14, 
cardiovascular disturbances15-17 and metabolic abnormalities12,18,19. Asymptomatic or 
normocalcaemic patients may have an early form of the disease, with smaller 
adenomas20,21. Long-term follow-up of conservatively treated pHPT patients shows that 
in most cases the disease is relatively stable. Progression has been documented in one 
fifth to one third of the patients9,22-24. Lowe et al. followed 37 normocalcaemic pHPT 
patients for 1-9 years and found that as many as 40% developed evidence of disease 
progression25. 
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Patients with pHPT also have an increased risk of death from mainly cardiovascular 
disorders and certain malignancies, of which breast cancer is the most frequent26,27,28-30. 
 
1.1.2 Treatment 
The only curative treatment of pHPT is surgical removal of the affected parathyroid 
gland(s). With improved techniques for preoperative localization, such as ultrasound 
and scintigraphy, and assays for intraoperative PTH monitoring, the surgery has 
become less extensive. Both the traditional four-gland exploration and minimally 
invasive surgery have a success rate of >95% and very low morbidity in the hands of 
experienced surgeons31,32. Since life expectancy and awareness of the disease have 
risen, an increasing proportion of elderly patients are referred to surgery. 
 
The change in the disease profile has lead to controversies over the advisability of 
recommending surgery to all patients, especially if they are asymptomatic and the 
diagnosis is discovered incidentally. This has resulted in the development of 
international guidelines for the surgical treatment of asymptomatic pHPT, in order to 
select patients with an expected beneficial effect. The current criteria are: age < 50 
years, serum calcium levels > 0.25 nmol/l above the upper limit of normal, creatinine 
clearance < 60 ml/min and BMD detected T-score < -2.5 at any site or previous 
fragility fracture33.  
 
After curative surgery, 9-62% of patients, depending on the time after surgery, have a 
persistently elevated PTH despite normocalcaemia34,35. Postoperative PTH elevation is 
associated with higher preoperative PTH, higher bone turnover markers and lower 
vitamin D levels34,36. The underlying aetiology is probably multifactorial. Possible 
causes are an increased need of calcium and phosphate in the remineralization of bone 
(hungry bone), vitamin D deficiency causing secondary hyperparathyroidism and 
reduced peripheral sensitivity to PTH35,37,38. The high preoperative PTH and low 
vitamin D levels suggest a beneficial effect of postoperative vitamin D supplementation 
in these patients, but there are no randomized trials which address this issue. 
 
1.1.3 Calcium and parathyroid hormone 
Calcium has several important physiological functions. One is to provide the mineral 
structure of bones and teeth and another is metabolic. Soluble calcium ions (Ca2+) in the 
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extracellular fluid are essential in a large number of enzymatic reactions, cell signalling 
and electrical membrane potentials necessary for normal cellular function. The skeleton 
serves as a reservoir of calcium. Precise control of the calcium level is critical and 
involves the parathyroid glands, the kidneys, the skeleton and the gut. The principal 
regulators of calcium homeostasis are PTH and 1,25-dihydroxyvitamin D 
(1,25(OH)2D). The free extracellular Ca2+ concentration is maintained within a narrow 
range (1.15-1.33 nmol/l). Approximately 50% of the total amount of circulating 
calcium is free: 40% is bound to proteins, mainly albumin, and about 10% to anions 
such as sulphate and citrate39.  
 
Parathyroid hormone is secreted by the chief cells of the parathyroid glands. It is 
initially synthesized as pre-pro-parathyroid peptide, which then undergoes post-
translational modifications, resulting in the biologically active 84-aminoacid protein. 
PTH has a short half-life and is degraded by the liver and kidney. It exerts its action 
through binding to widely distributed PTH receptors, mainly expressed in bone and the 
kidneys40,41. 
 
PTH is a major regulator of calcium and phosphate homeostasis. Its main function is to 
maintain the extracellular calcium concentration within physiological limits through 
actions on bone metabolism, renal function, vitamin D activation and gastrointestinal 
absorption.  
 
Ca2+ exerts its action on the parathyroid glands by binding to a surface-bound G-
coupled receptor, the calcium sensing receptor42. A change in the secretory rate of PTH 
in response to low Ca2+ takes place in a matter of seconds and the net rate of PTH 
synthesis increases within 30 minutes43. PTH elevates serum Ca2+ concentrations by 
increasing calcium reabsorption in the loop of Henle and the distal tubule of the kidney 
and by stimulating the conversion of 25-hydroxyvitamin D (25-OH-D) to the active 
1,25(OH)2D in the proximal tubule. PTH also releases Ca2+ and phosphate from the 
skeleton. At the same time, PTH has a phosphaturic effect by stimulating the excretion 
of phosphate in the proximal tubule of the kidney (Figure 1). This is thought to 
compensate for the extra phosphate released from the skeleton. 
 
PTH production is increased by phosphate and inhibited by Ca2+ and 1,25(OH)2D44. 
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 Figure 1. Effects of PTH. PTH increases serum Ca2+ through the activation of vitamin D and 
reabsorption of Ca2 in the kidney, and through releasing Ca2 from the bone. Secretion is stimulated by 
low Ca2+, high phosphate and low 1,25(OH)2D and inhibited by high Ca2+ and 1,25(OH)2D. 
PTH=parathyroid hormone, P=phosphate, Ca2+=ionized calcium, 1,25(OH)2D=1,25-dihydroxy-vitamin 
D 
 
 
1.2 ASSOCIATION TO BREAST CANCER 
PHPT is associated with an increased risk of developing malignant disorders. Certain 
malignant tumours are overrepresented, for example breast cancer, colon cancer, cancer 
in the kidneys and non-melanotic skin cancer8,27,29. The increased risk of breast cancer 
persists for at least 15 years after parathyroid adenomectomy (PTX)27,30. Breast cancer 
patients have a high incidence of hypercalcaemia, and pHPT may be one of the causes 
apart from bone metastases45. PHPT was found to be more common in a breast cancer 
population than in patients with differentiated thyroid cancer and it was unrelated to 
clinical stage or anti-tumour therapy46. In a group of untreated breast cancer patients, 
the association was no longer significant when age was taken into account47. Serum 
calcium and 25-OH-D concentrations have also been associated with an increased risk 
of breast cancer, but data are not consistent48-54. Breast cancer and pHPT share several 
other characteristics: both typically affect postmenopausal women and both are 
associated with ionized radiation55,56 and obesity57,58.  
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These common features suggest potential shared etiological pathways or risk factors of 
pHPT and breast cancer, such as predisposing genetic or environmental factors. There 
could also be an increased susceptibility to one disease as a consequence of the other, 
but that is less likely because the risk of breast cancer persists after surgically treated 
pHPT27. Little is known about any possible causal relationship. Familial accumulations 
of pHPT and breast cancer, as well as isolated cases with high penetrance susceptibility 
genes, have been reported59,60. 
 
Whether pHPT affects the aggressiveness of breast cancer is not known. One study 
found an association between serum calcium levels and increased tumour 
aggressiveness in premenopausal and/or overweight women61.  
 
 
1.3 VITAMIN D 
Vitamin D supplies in humans come from exposure to sunlight and dietary intake. 
Ultraviolet radiation from the sun converts 7-dehydrocholesterol to cholecalciferol 
(vitamin D3) in the skin. The quantity of vitamin D3 formed in the skin depends on the 
duration and intensity of sunlight exposure. Vitamin D3 can be stored in fat and in the 
liver. Vitamin D is hydroxylated twice, first in the liver to 25-hydroxyvitamin D (25-
OH-D) and a second time in the kidney, where it is converted by 1α-hydroxylase to its 
biologically active form, 1,25-dihydroxyvitamin D (1,25(OH)2D). 25-OH-D is used to 
determine a person’s vitamin D status since it is more stable and its serum 
concentration is 500-1000 times higher than 1,25(OH)2D’s. 1,25(OH)2D binds to the 
vitamin D receptor, an intracellular hormone receptor, to exert its effect. Vitamin D is 
involved in the regulation of cellular metabolism and differentiation, bone metabolism 
and inflammation. It plays a role in calcium homeostasis, where 1,25(OH)2D increases 
serum calcium concentrations by enhancing absorption from the intestine and 
resorption of calcium from bone (Figure 1). PTH stimulates the conversion to 
1,25(OH)2D, while 1,25(OH)2D has a negative effect on PTH secretion. Other 
regulators of 1,25(OH)2D are phosphorus, calcium and fibroblast growth factor 
2344,62,63. 
 
There is no globally accepted cut-off defining vitamin D deficiency and insufficiency. 
The most widely used (recommended by the Institute of Medicine, USA64 and the 
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Danish Sundhedsstyrelsen) is deficiency defined as a 25-OH-D concentration below 25 
nmol/l and insufficiency as ≤ 50 nmol/l. Attempts to define vitamin D deficiency are 
often based on studies aimed at determining the point at which vitamin D cannot 
further suppress the PTH level, resulting in a wide range of values 65-67. Other studies 
on 25-OH-D levels in relation to clinical outcomes, such as BMD, fractures and 
colorectal cancer, found advantages at 25-OH-D concentrations above 50-75 nmol/l 
68,69. A large cross-sectional analysis on more than 300,000 individuals showed a 
continuous decline in PTH with rising 25-OH-D and no inflection point or plateau 70.  
 
Vitamin D insufficiency is one of the causes of secondary hyperparathyroidism. A 
chronic, low vitamin D concentration has an adverse effect on the skeleton, leading to 
rickets in children and osteoporosis/osteomalacia in adults. Many extra-skeletal 
conditions, such as autoimmune diseases, malignancies and cardiovascular morbidity 
and mortality, have been associated with low vitamin D levels in observational 
studies51,71-73. However, the existing data are inconclusive as to causality.  
 
Supplementation with vitamin D and calcium has a putative positive effect on bone 
health and fracture prevention, but the evidence is inconsistent74,75. In a recent pooled 
analysis of eleven randomized clinical trials, looking at quartiles of actual intake of 
vitamin D, high-dose vitamin D supplementation (≥800 IU daily) was somewhat better 
for preventing hip fracture and any non-vertebral fracture in patients 65 years of age or 
older76. There is not enough evidence for benefits of vitamin D and/or calcium 
supplementation in extra-skeletal conditions and mortality64,77,78. In a pooled analysis, 
vitamin D and calcium reduced mortality, but data did not support an effect of vitamin 
D alone79. 
 
A low concentration of vitamin D is more prevalent in patients with pHPT than in 
geographically matched populations80-83. Vitamin D deficiency seems to be associated 
with more severe pHPT, in terms of higher PTH levels, larger adenomas and lower 
BMD82,83. It is also associated with a persistent PTH elevation after curative surgery36. 
Possible explanations for the relationship between pHPT and low vitamin D levels are 
stimulation of adenoma growth or inhibition of the production of vitamin D in skin and 
liver by the elevated level of 1,25(OH)2D, caused by an increased conversion to 
1,25(OH)2D in the kidney. Enhanced inactivation of 25-OH-D in the liver has also been 
suggested84. 
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The Guidelines for management of asymptomatic pHPT recommend repletion to a 25-
OH-D concentration > 50 nmol/l to distinguish primary from secondary 
hyperparathyroidism33. Supplementation with vitamin D in untreated pHPT patients 
may decrease PTH levels and bone turnover, but there are no randomized trials to prove 
any beneficial effects85. Since low vitamin D is common in pHPT patients and 
associated with a persistent elevation of PTH after surgery, postoperative vitamin D 
supplementation might have positive effects on bone health and metabolic disturbances 
associated with pHPT.  
 
However, studies on repletion after parathyroid surgery are sparse and no randomized 
trial has been conducted. A reduction in PTH concentration has been shown, but no 
effect on BMD86,87. 
 
 
1.4 METABOLIC AND CARDIOVASCULAR COMPLICATIONS 
1.4.1 Cardiovascular morbidity and mortality 
Serum levels of PTH have been associated with cardiovascular morbidity and mortality 
in the general population88-90. An increase in cardiovascular mortality in patients with 
pHPT has been well documented in European studies9,26,91-96. North American studies 
are incongruent with these results but an association has been demonstrated between 
high calcium levels and increased cardiovascular mortality97,98. A possible explanation 
is that patients diagnosed in more recent years have less severe disease. However, Yu et 
al. found that patients with untreated mild pHPT, diagnosed between 1997 and 2006, 
had an increased cardiovascular morbidity and mortality compared to the general 
population, but mortality data in mild pHPT are scanty99. 
 
Most studies indicate that PTX results in a lower mortality26,100,101. The pathogenesis of 
the increased risk of cardiovascular disease in pHPT has not been established. PHPT 
has been associated with cardiac abnormalities in structure and function, such as left 
ventricular hypertrophy, diastolic dysfunction and conduction disturbances28. Several 
aspects of the metabolic syndrome have been linked to pHPT, such as increased body 
weight57, hypertension, dyslipidaemia, glucose intolerance and insulin resistance102-105. 
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PTH in normocalcaemic patients is also independently associated with hypertension, 
dyslipidemia, body mass index (BMI) and insulin sensitivity106,107. 
 
1.4.2 Hypertension and pHPT 
Hypertension is common in pHPT even in its mild form105,108,109. The cause of this 
association is not entirely clear, but possible mechanisms are increased total peripheral 
resistance, disturbances in the renin-angiotensin-aldosteron axis110 and endothelial 
dysfunction16,111,112. Associations with other cardiovascular risk factors such as diabetes 
complicate interpretations. Both prolonged elevation of calcium and PTH are 
associated with an increase in blood pressure113-115. Reversible endothelial dysfunction 
seems to precede structural vascular changes in pHPT111,112. Studies on PTX’s effect on 
hypertension have produced contradictory results, where some report a decrease in 
blood pressure102,105,108,116 and others show no effect117,118. Ambulatory monitoring of 
blood pressure (ABP) is superior to single office measurements in predicting the risk of 
cardiovascular complications119. Data on ABP in pHPT are scanty and not 
conclusive108,117,118,120,121. In view of the lack of agreement concerning PTX’s effect on 
hypertension, the presence of hypertension in pHPT patients is currently not an 
indication for PTX122. 
 
 
1.4.3 Glucose metabolism and pHPT 
Data on insulin resistance in pHPT, especially mild pHPT, are sparse and 
contradictory123. Increased incidences of non-insulin dependent diabetes mellitus, 
insulin resistance and decreased glucose tolerance have been reported19,103,124-126. PTH 
levels are associated with insulin sensitivity assessed by the hyperglycaemic clamp107. 
A plausible biological mechanism could be that PTH influences intracellular calcium 
levels and thereby insulin sensitivity. Both hypercalcaemia and hypophosphataemia 
have been linked to reduced insulin sensitivity103,127. PTX has been found to reduce 
abnormalities in glucose metabolism125,126,128 but not in all studies129. In a study of 
patients with mild pHPT, PTX had a positive effect on BMD, but did not benefit insulin 
resistance and other metabolic risk factors130. 
 
Insulin-like growth factor I (IGF-I) plays an important role in the regulation of cell 
proliferation and differentiation. It is synthesized mainly in the liver and regulated by 
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growth hormone. It exerts its effect in most tissues, where it is involved in the 
pathogenesis of insulin resistance, metabolic syndrome and cardiovascular disease131. 
IGF binding protein 1 (IGFBP-1), a protein of predominantly hepatic origin, modulates 
the bioactivity of IGF-I. In addition, IGFBP-1 seems to have insulin-sensitizing, blood-
pressure lowering and anti-atherosclerotic properties on its own132,133. IGFBP-1 is a 
marker of insulin secretion134. Increasing levels of IGFBP-1 seem to have favourable 
effects on insulin sensitivity, hypertension and other cardiovascular risk factors133,135. 
There are just a few studies on IGFBP-1 and pHPT. Jehle et al. reported higher 
concentrations of IGFBP-1 in pHPT patients than in healthy controls136 but a smaller 
study found no difference137. In the latter study, on 13 patients and nine controls, the 
response of IFGBP-1 to oral glucose suggests an improvement in insulin sensitivity 
after PTX. 
 
 
1.5 EFFECTS ON BONE 
PTH has both anabolic and catabolic effects on bone, depending on whether the 
exposure to PTH is continuous as in pHPT (catabolic effects) or intermittent as during 
treatment with exogenous PTH in osteoporosis (anabolic effects). Intermittent exposure 
to PTH has an anabolic effect through enhanced osteoblast formation and survival 
whereas chronic PTH stimulation, as in pHPT, stimulates osteoclast formation, activity 
and survival138. The anabolic effects of PTH are at least partially mediated by a local 
synthesis of insulin-like growth factor I (IGF-I) in the osteoblasts139. In the Western 
world today, severe skeletal disease in pHPT, such as osteitis fibrosa cystica, is rare. 
However, many patients suffer from osteopenia or osteoporosis and the current 
guidelines cite the latter as an indication for surgery in asymptomatic pHPT33.  
 
In pHPT, there is a 50-60% increase in bone turnover and number of osteoclasts and 
osteoblasts, but decreased activity of the individual bone cells, leading to a prolonged 
active formation period and a tendency to a longer remodelling period, resulting in 
shallower resorption sites140,141. There is also a disturbed mineralization, which may be 
due to hypophosphataemia induced by PTH or low concentrations of 25-OH-D.  
 
Most studies on BMD using dual X-ray absorptiometry (DXA), microcomputed 
tomography and analyses of iliac crest bone biopsies in patients with pHPT, show that 
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cortical bone undergoes reductions of cortical width and porosity that recover after 
PTX, while the cancellous bone is relatively preserved14,142-144. BMD measured by 
DXA, typically shows the greatest reduction in sites rich in cortical bone, such as the 
1/3 proximal forearm, and a more modest reduction or even preserved BMD in the 
lumbar spine, dominated by cancellous bone141. Recently, studies using high-resolution 
peripheral quantitative computed tomography (HR-pQCT) have demonstrated both 
trabecular and cortical abnormalities at the radius and tibia, resulting in decreased 
whole bone and trabecular stiffness145,146.  
 
After PTX, bone turnover decreases, with an early fall in the concentration of 
resorption markers, while markers of bone formation decrease more slowly147-149. As a 
result, the BMD increases, predominantly in the lumbar spine and hip, and to a lesser 
extent in the forearm130,146,150-153. The greatest improvement occurs during the first 
postoperative year154. The majority of the patients in these studies have mild pHPT, and 
BMD improved after PTX even in patients who did not meet the criteria for surgical 
treatment153. Patients randomized to observation had a stable or slightly decreased 
BMD during follow-up (one or two years)130,152,153,155. In an observational study of 
patients with pHPT for 10 to 15 years, BMD decreased significantly after 5-10 
years23,24. A quarter to one third of the patients met at least one criterion for surgery 
according to guidelines during the follow-up. 
 
Bone mineral density is an important predictor of fracture risk. A number of cohort 
studies have reported an increased risk of fractures at several sites in patients with 
pHPT, even 10 years before diagnosis156-158. The fracture risk is increased not only at 
sites rich in cortical bone, as suggested by the DXA findings, but also in sites rich in 
cancellous bone, such as the lumbar spine and hip. This is in accordance with the 
above-mentioned recent finding of trabecular abnormalities.  
 
No randomized studiy has been published on the effect of surgery on fracture risk in 
pHPT, but three cohort studies show a decreased risk of fractures of the hip, femur, 
forearm and upper arm159-161. 
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2 AIMS OF THE THESIS 
• To analyse all-cause mortality within 30 days and one year after parathyroid 
adenomectomy during five decades. 
 
• To investigate whether a history of primary hyperparathyroidism affects the risk 
of mortality or factors predictive of prognosis and response to therapy in 
women with a subsequent breast cancer. 
 
• To study the effects of surgery and postoperative vitamin D supplementation on 
insulin resistance, ambulatory blood pressure and other cardiovascular risk 
factors in patients with primary hyperparathyroidism. 
 
• To study the effect of postoperative vitamin D supplementation on parathyroid 
hormone levels and bone mineral density in patients with primary 
hyperparathyroidism. 
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3 PATIENTS AND METHODS 
3.1 STUDIES I AND II 
3.1.1 Quality registers 
The Swedish Cancer Registry is a well-validated register with 3-4% underreporting162. 
Since 1958, all malignant and a few benign tumours, including parathyroid adenomas, 
are reported to the register, by both the treating physician and the pathologist 
establishing the diagnosis. The registry includes date of diagnosis and type of tumour. 
Diagnoses are coded using the International Classification of Diseases 7th revision 
(ICD-7).  
 
Causes of death are reported to the Cause of Death Registry at the National Board of 
Health and Welfare. The registry includes all deaths from 1952 onwards among 
registered Swedish residents. It also contains the underlying and contributory causes of 
death from the physician’s death certificate in accordance with ICD-7, 8 and 9 and date 
of death. Underreporting is 0.5% and the proportion of misclassification was 1.2±0.3% 
(year 1998, www.socialstyrelsen.se).  
 
Matching between registers can be achieved by means of the individual National 
Registration Number that is allocated to every Swedish resident. 
 
 
3.1.2 Design and patients: Study I 
In a cohort study of 14,635 patients subjected to PTX, generated from the Swedish 
Cancer Registry during January 1961 to December 2004, postoperative mortality within 
30 days and one year was analysed. All patients had a histopathologically verified, 
single parathyroid adenoma. Neither cancer, nor hyperplasia were included. Date and 
cause of death were derived from the National Cause-of-Death Registry. 
 
3.1.3 Statistical analysis: Study I 
The person-year at risk was counted from the date of entry into the cohort until death, 
emigration or the end of the observation period, i.e. 31 December 2004. The entire 
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Swedish population, standardized for age, gender and time period was used as control 
to calculate standard mortality ratios (SMR). SMR were calculated as the ratio of the 
observed to the expected number of deaths and used as an indicator of risk. Nationwide 
statistics from the Causes-of-Death Registry include annual sex- and age-specific 
mortality rates for different ICD codes. The expected number of deaths in the observed 
population was calculated by multiplying the number of person-years at risk for each 5-
year age group, gender and calendar year, by the corresponding age, gender and 
calendar year-specific mortality rates in the general population. The 95% confidence 
interval (CI) of SMR was calculated on the assumption that the number of deaths in 
various categories followed the Poisson distribution. Various stratification studies were 
conducted, using age and calendar year at entry, the duration of follow-up, attained age, 
gender and various combinations. 
 
 
3.1.4 Design and patients: Study II 
This was a nested case-control study comparing breast-cancer patients with and without 
a history of surgically cured pHPT. The study population was retrieved from the 
Swedish Cancer Registry. Requisites for inclusion of cases were parathyroid 
adenomectomy of a single parathyroid adenoma (ICD-7 1951) and a subsequent 
diagnosis of invasive breast cancer (ICD-7 170). For each patient, five control subjects 
with breast cancer but no history of pHPT, matched for age and time period, were 
enrolled. To minimize confounding by diagnosis, we excluded all cases with a breast 
cancer diagnosis discovered prior to primary hyperparathyroidism (n=59). All males 
were excluded, as were all women with a diagnosis of breast carcinoma in situ. The 
national registration number, a unique identifier for each Swedish resident, was used 
for linkage to the regional breast cancer registers in Stockholm and Uppsala and the 
Swedish Cause of Death Registry. Data on tumour size, stage, lymph node and 
hormonal receptor status, date and cause of death were retrieved from the registers. 
 
Seventy-one women with breast cancer diagnosed after surgery for pHPT and 338 
controls were identified during the period from January 1 1992 to December 31 2006. 
The American Joint Committee on Cancer’s staging system for breast cancer was 
used163. 
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3.1.5 Statistical analysis: Study II 
Statistical analysis was performed with the PASW for Windows statistical package 
18.0 (PASW Inc; Chicago, IL, USA). Student’s two-tailed, unpaired t-test was used to 
compare mean tumour size between the cases and control subjects. The distribution of 
tumour characteristics of cases and controls was compared by Pearson’s chi-square test. 
When cells had expected counts less than 5, a corresponding exact test was applied.  
 
Survival time was calculated as the number of months between the date of diagnosis 
and whichever occurred first: date of death, date or end of follow-up. Breast cancer 
survival is presented in a Kaplan-Meier plot and tested with the Logrank test.  P < 0.05 
was considered to be statistically significant. 
 
 
 
 
 
 
3.2 STUDIES III AND IV  
3.2.1 Design 
A randomized double-blind clinical trial (ClinicalTrials.gov Identifier: NCT00982722) 
to evaluate the effect of vitamin D supplementation after PTX was conducted at the 
Karolinska University Hospital during the period from April 2008 to November 2010. 
After successful PTX the patients were randomized to either one year of treatment with 
daily oral cholecalciferol 800 IU x 2 and calciumcarbonate 1 g x 2 (D+) or 
calciumcarbonate 1 g x 2 alone (D-) (Figure 2). The study was blinded for all the 
researchers, physicians, nurses and patients.  
 
The primary end-point was the change in PTH after PTX and treatment with the study 
medication. For study III, secondary end-points were vitamin D levels, changes in 
metabolic risk factors, body composition and ambulatory blood pressure. Secondary 
end-points for study IV were vitamin D levels, biochemical markers of bone turnover 
and bone mineral density. 
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Figure 2 Flow chart of the study 
 
  
 
 
3.2.2 Patients 
Patients with pHPT planned for surgery were eligible for the study. Exclusion criteria 
were age under 18, manifest osteoporosis at pHPT diagnosis, persistent hypercalcaemia 
after surgery, postoperative hypocalcaemia requiring vitamin D treatment, glomerular 
filtration rate (GFR) <40 ml/min., pregnancy, breast-feeding or if the treating physician 
considered it unsuitable for the patient to participate for other reasons. Patients on 
vitamin D treatment, prescribed for medical reasons, were not included in the study. 
 
A total of 159 consecutive patients were enrolled, but after PTX, nine of them met 
exclusion criteria; 150 patients were randomized, 75 patients in each arm. They were 
followed during one year. 135 patients had a complete follow-up: the fifteen who 
159 pHPT patients eligible at study screening 
Parathyroidectomy 
Randomized n=150 
n=75 (56 women) 
  
cholecalciferol 800 IU x 2 + 
 calcium carbonate 500 mg x 2 
!
n=75 (63 women) 
 
calcium carbonate 500 mg x 2 
!
n=66 
Analysed for outcomes 
per protocol 
n=69 
Analysed for outcomes 
per protocol 
n=9 
Lost to follow-up 
n=6 
Lost to follow-up 
9 pHPT excluded 
•  hypercalcemia (n=7) 
•  lithium treatment   (n=1) 
•  manifest osteoporosis (n=1) 
!
Primary end-point: !!PTH!
Secondary end-points: 
•  24AMB blood pressure 
•  metabolic risk factors 
•  body composition 
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dropped out were followed for median 6 months (min-max 1-9 months).  Reasons for 
termination were patient’s own will (n=11), emigration (n=1), deceased (n=2) and 
symptomatic vitamin D deficiency (n=1).   
BMI was calculated at baseline as weight (kilograms) divided by the square of height 
(metres). Patients with insulin treatment (n=2) were excluded from the analyses of 
glucose, insulin and HOMA-IR. 
 
All patients gave written consent to participation. The study complied with the Ethical 
Principles of the World Medical Association Declaration of Helsinki, and was 
approved by the Medical Products Agency in Sweden and by the Local Ethics 
Committee, Regionala etikprövningsnämnden, EPN, of Stockholm, Sweden.  
 
3.2.3 Methods 
3.2.3.1 Laboratory methods 
Blood and urine samples were collected after an overnight fast at six ± two weeks 
before surgery, at randomization and after six and twelve months of treatment. Plasma 
concentrations of intact PTH, insulin-like growth factor I (IGF-I) and insulin and serum 
concentrations of procollagen type 1 aminoterminal propeptide (P1NP) and c-terminal 
telopeptide of type 1 collagen (βCTx) were determined with electrochemiluminescence 
immunoassay on the Modular E system (Roche Diagnostics GmbH, Mannheim, 
Germany). Serum ionized calcium (Ca2+) was analysed on ABL 800 (Radiometer, 
Copenhagen, Denmark). Plasma concentrations of phosphate, creatinine, glucose, total 
cholesterol, triglycerides (TG), HDL and LDL were measured using the Synchron LX 
20 system (Beckman Coulter Inc., Brea, CA). Serum concentrations of 25-OH-D were 
measured by chemiluminescence on Liason XL® (DiaSorin, Inc Stillwater, USA); 
values below 50 nmol/l were considered to represent vitamin D insufficiency33. The 
inter-assay coefficient of variation (%CV) is 4.6% at 15.5 nmol/L and 2.7% at 68.3 
nmol/l; intra-assay %CV is 4.4% at 15.5 nmol/l and 2.6% at 68.3 nmol/l. 
 
Estimated renal function (GFR ml/min/1.73 m2) was derived by Cockroft-Gault’s 
formula: GFR = (140-age in years) x (weight in kilograms/plasma creatinine) x (1.23 in 
men or 1.04 in women). An in-house radioimmunoassay (RIA) according to the method 
of Póvoa et al. determined IGFBP-1 concentrations in serum164. The sensitivity of the 
RIA was 3 µg/l and the intra- and inter-assay CVs were 3% and 10%, respectively.  
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Estimates of insulin resistance were calculated using the homeostatic model assessment 
(HOMA-IR): insulin resistance=fasting glucose x fasting insulin/22.5 after conversion 
of insulin levels from pmol/l to µU/ml by multiplication with a factor 6.945165. 
 
3.2.3.2 Bone mineral density and body composition 
Areal bone mineral density (BMD, g/cm2) of the total body, total hip, femoral neck, 
lumbar spine, non-dominant forearm (ultradistal (UD) and 1/3 proximal radius) and 
body composition was estimated using dual energy x-ray absorptiometry (DXA). The 
same instrument (Lunar Prodigy Advance, #PA+41562, GE Healthcare) was used for 
all the patients. Osteoporosis was defined as a T-score at any site -2.5 standard 
deviations below the value for white women aged 20-29 years. The precision error was 
0.009 SD g/cm2 in the lumbar spine, 0.010 SD g/cm2 in the total hip and 0.007 SD 
g/cm2 in the femoral neck. The precision error of the forearm was not measured. 
 
3.2.3.3 Ambulatory blood pressure 
Ambulatory blood pressure monitoring (24h ABP) was performed with a standardized 
ambulatory blood pressure device (Meditech ABPM-04 monitor (PMS Instruments, 
Maidenhead, United Kingdom) that was applied around the patient’s non-dominant 
arm. Daytime was defined as the time from wakening to bedtime (07.00-23.00 in most 
cases) and night-time as the time the study participant spent in bed. The ambulatory 
device was set to record ABP and heart rate (HR) at 30-minute intervals during daytime 
and 60-minute intervals during night-time. If the recording failed, a new measurement 
was automatically done after 2 minutes. Patients were instructed to continue their usual 
daily activities while wearing the device and to continue any anti-hypertensive 
treatment. 125 patients completed pre-and postoperative AMB. 
 
3.2.4 Statistical analysis and sample size calculation 
Statistical analysis was performed with the IBM SPSS Statistics version 20. Since data 
did not follow a normal distribution, they were expressed as median and interquartile 
range. Intra-individual analyses were performed with the Wilcoxon signed rank sum 
test. Comparison between groups was performed with the Mann-Whitney U-test for 
unpaired data; the Kruskal-Wallis one-way analysis of variance was used for 
comparison of more than two independent continuous variables and the chi-square test 
was used for analysis of the distribution of categorical variables. Univariate analyses of 
relationships between variables were assessed with Spearman’s ρ-correlation test. 
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Partial correlations were used to assess the relationship between delta BMD and PTH 
and 25-OH-D (controlling for age, gender, weight, smoking and creatinine).  
All tests were done two-tailed, and p<0.05 was considered to be statistically significant. 
 
The size of the cohort was determined by a power analysis. Based on data from a 
European study showing that 90 % of a population of patients with pHPT had a vitamin 
D insufficiency81 and a Swedish study where 28 % of the patients had an increased 
level of PTH 8 weeks after PTX166, we expected PTH to be within the normal range, 
after PTX, in 72% of  patients not receiving vitamin D and in 97 % of those treated 
with vitamin D. Since data on the effect of vitamin D on postoperative PTH levels are 
scarce, we assumed a normal PTH level in two-thirds of the patients with vitamin D 
supplementation. Thus, with a significance level of 0.05 and a power of 80%, we 
calculated a sample size of 71 patients in each group. To compensate for dropouts 
during the study, we chose to enrol 75 patients per group. 
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4 RESULTS 
4.1 STUDY I 
Of the 14,635 pHPT patients in the cohort, 79% were women. The observation time 
was more than 166,000 person-years. The mean age of the patients increased from 53 
years in the period 1961–71 to 64 years in 1992–2004 (p<0.0001). Nearly 3000 of the 
pHPT patients were 75 years of age or more at the time of PTX and this age group 
constituted more than a quarter of the cases in the most recent period (1997-2004) 
(Figure 3).  
 
 
Figure 3 Age distribution in different time periods 
 
 
 
During the entire study period, 185 patients died within one month after PTX and 365 
died during the next eleven months. An analysis of the 30-day mortality over time 
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showed a decrease from 4.2% during 1961-1976 to 0.4% 1997-2004. Mortality in the 
period from day 31 to day 365 after PTX ceased to be significantly increased from 
1987 onwards (Table 1).  
 
Table 1. Standard mortality ratio with 95% confidence interval in different time 
periods, after parathyroid adenomectomy. 
 1st month 2-12 months 
 n % SMR 95% CI n SMR 95% CI 
1961-1976 105 4.2 % 34.8 28.5-42.1 66 2.05 1.58-2.60 
1977-1986 36 0.9 % 6.21 4.35-8.59 116 1.77 1.46-2.12 
1987-1996 31 0.6 % 3.52 2.39-5.00 118 1.17 0.97-1.40 
1997-2004 13 0.4 % 2.27 1.21-3.88 65 1.07 0.82-1.36 
Total number 185 1.3 % 7.92 6.82-9.15 365 1.40 1.26-1.56 
 
 
 
 
Table 2 shows the 30-day mortality in different age and calendar year groups. Mortality 
within 30 days after PTX in the period 1997–2004 among patients 75 years or older 
was 1.0%. The dominant causes of mortality during the first month after PTX were 
cardiovascular (37%), endocrine (32%) and malignancy-related (17%), demonstrable in 
both genders and in all the investigated age groups (Figure 4). Of the patients who died 
within the first year after PTX, 51% did so from a cardiovascular disorder. 
 
 
Figure 4 Causes of death during the first month after parathyroidectomy. 
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4.2 STUDY II 
The mean age at diagnosis of breast cancer was 69 years in both groups (standard 
deviation (SD) 11 years, 95% confidence interval (95%CI) 68-70 years). The mean 
interval between parathyroid adenoma operation and breast cancer diagnosis was 91 
months (SD 68 months, 95%CI 72-111 months), ranging from 1 to 292 months. 
Tumour size, stage, axillary lymph node status and hormone receptor status are 
presented in Table 3.  
 
 
 
Table 3 Tumour characteristics in women with pHPT + breast cancer (cases) and 
women with breast cancer only (controls). 
 Cases 
(n=71) 
Controls 
(n=338) 
p-value 
Tumour size (mm±SD) 18±10 20±14 0.27 
   Missing 4 29  
Axillary lymph node status    
   Negative 35 (59%) 176 (65%)  
        1-3 positive nodes 11 (19%) 63 (23%)  
        ≥4 positive nodes 13 (22%) 32 (12%) 0.11 
   Missing 12 (17%) 67 (20%)  
Tumour stage    
   I (T1+N0) 29 (46%) 149 (51%)  
   IIa (T1+N1 or T2+N0) 25 (40%) 77 (27%)  
   IIb (T2+N1 or T3+N0) 9 (14%) 49 (17%)  
   III (T3+N1 or T4) 0 (0%) 4 (1%)  
   IV (M1) 0 (0%) 11 (4%) 0.13c 
   Undefined 8 (11%) 48 (14%)  
Hormone receptor status    
   Positivea 46 (88%) 217 (84%)  
   Negativeb 6 (12%) 42 (16%) 0.38 
   Missing 19 (27%) 79 (23%)  
aER positive, PR positive or negative according to local laboratory and clinical 
standards 
bER and PR negative 
cExact Pearson Chi-Square test  
 
 
None of the prognostic factors analysed in this study differed between the women with 
and those without a history of pHPT. Mean time of follow-up was 80 months (SD 59 
months, 95%CI 74-86). At December 31 2009, 29 (41%) cases and 150 (44%) controls 
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had died. There was no statistically significant difference between the two groups in the 
cumulative breast cancer specific survival (Figure 5). 
 
Figure 5 Kaplan-Meier plot of breast cancer specific survival in women with 
pHPT+breast cancer (cases) and women with breast cancer only (controls). 
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4.3 STUDIES III AND IV 
Patient characteristics and biochemical data at baseline and after PTX are shown in 
Tables 4 and 5. The calcium level was normalized six weeks after PTX in all patients, 
but 50% had a persistently high PTH (>65 ng/l). Vitamin D levels were lower in 
patients with a high postoperative PTH (25-OH-D 39 nmol/l (31-44) vs. 42 nmol/l (32-
52), p=0.027) and they had larger adenomas (534 g (310-1038) vs. 333 g (204-819), 
p=0.003) and their preoperative PTH levels were higher (141 ng/l (119-169) vs. 94 (82-
108), p<0.001) but creatinine did not differ (data not shown). The incidence of 25-OH-
D below 50 nmol/l at baseline was 76% and was similar in men and women. 
 
Table 4. Clinical characteristics 
 
n=150 
Age (years, median (min-max)) 60 (30-80) 
Women / men (n) 119 / 31 
Women ≤50 yrs / >50 yrs (n) 19 / 100 
BMI (kg/m2, median (min-max)) 26 (17-44) 
Weight of adenoma (mg, median (min-max) 450 (75-27800) 
Multiglandular disease (n) 4 
Vitamin D < 50 nmol/l (n (%)) 114 (76%) 
Osteoporosis (n (%)) 69 (46%) 
Smokers (n (%)) 23 (15%) 
Diabetes (n (%)) 8 (5%) 
Antihypertensive treatment  67 (45%) 
Loop diuretics 26 (17%) 
ACE inhibitors 31(21%) 
Betablockers 32 (21%) 
Calcium channel blockers 16 (11%) 
Other relevant medication 
 Statins 24 (16%) 
Steroids 3 (2%) 
Oestrogen, systemic 6 (4%) 
Insulin 2 (1%) 
Oral antidiabetics 6 (4%) 
BMI=body mass index 
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Table 5. Biochemistry before and after parathyroid adenomectomy (PTX) 
 
Baseline After PTX   
 
Median IQR Median IQR p (W) 
S-25-OH-D (75-250 nmol/l) 40 31-49 42 33-54 0.004 
P-PTH (10-65 ng/l) 116 89-145 65 53-68 <0.001 
S-Ca2+ (1.15-1.33 mmol/l) 1.43 1.39-1.43 1.25 1.22-1.27 <0.001 
P-Phosphate (0.75-1.4 mmol/l) 0.83 0.74-0.92 1.0 0.92-1.1 <0.001 
P-Creatinine (♀<90, ♂<100 
µmol/l) 65 56-76 67 58-75 0.400 
GFR Creatinine (ml/min) 97 79-117 95 79-115 0.900 
P-Glucose (4.0-6.0 mmol/l)a 5.2 4.9-5.6 5.2 4.8-5.6 0.022 
S-Insulin (18-173 pmol/l)a 66 43-97 58 37-95 <0.001 
HOMA-IRa 2.2 1.4-3.3 1.8 1.2-3.2 <0.001 
S-IGF-I (110–270 µg/l) 144 117-179 138 115-172 <0.001 
S-IGFBP1 30 21-49 37 21-54 0.046 
S-Cholesterol (3.3-7.8 mmol/l) 5.6 4.8-6.1 5.5 4.9-6.3 0.134 
P-HDL (♀01.0-2.7, ♂0.8-2.1 
mmol/l) 1.4 1.2-1.8 1.4 1.2-1.8 0.825 
P-LDL (1.4-5.3 mmol/l) 3.5 2.8-4.1 3.5 2.8-4.1 0.161 
S-Triglycerides (0.45–2.6 
mmol/l) 0.98 0.75-1.40 0.96 0.70-1.52 0.256 
S-P1NP (µg/l) 62 47-89 57 42-78 <0.001 
S-βCTx (ng/l) 545 388-707 318 216-455 <0.001 
a patients with insulin treatment were excluded from the analysis. 
W=Wilcoxon signed rank sum test for paired data 
25-OH-D=25-hydroxyvitamin D, PTH=parathyroid hormone, Ca2+=ionized calcium, GFR=glomerular 
filtration rate, HOMA-IR=homeostatic model assessment insulin resistance, IGF-1=insulin-like growth 
factor 1, IGFBP1=IGF binding protein1, HDL=high density lipoprotein, LDL=low density lipoprotein 
       
At follow-up after twelve months, the D+ group had a significantly higher level of 
vitamin D and lower PTH (Table 6). 19 % (n=26) had a persistently high concentration 
of PTH (D+ n=9, D- n=17). Only two patients had 25-OH-D below 50 nmol/l in the D+ 
group, compared to 36 patients in the D- group. 12 patients, all in the D- group, had a 
combination of high PTH and 25-OH-D < 50 nmol/l. 
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4.3.1 Study III 
Patients with 25-OH-D in the lowest quartile at baseline (< 31 nmol/l) had higher levels 
of fP-glucose (median 5.4 (IQR 5.1-6.3) vs. 5.2 (4.9-5.5) mmol/l); insulin (79.4 (53.5-
129.0) vs. 60.5 (43.1-87.9), HOMA-IR (2.7 (1.7-5.2) vs. 2.0 (1.4-3.1) and triglycerides 
(1.3 (0.9-1.8) vs.0.9 (0.7-1.2); p<0.05 for all parameters. Plasma glucose, insulin, 
HOMA-IR and IGF-I decreased after PTX, while IGFBP1 increased. rIGFBP-1 
correlated to rPTH (r=0.18; P=0.03) and was inversely correlated to rinsulin (r=-
0.26; p=0.002) and rHOMA-IR (r=-0.25; p=0.002). 
 
After one year of study medication, the D+ group had a lower serum concentration of 
IGF-1 than the D- group (Table 6). All other biochemistry (except PTH and vitamin D, 
as mentioned above) was unchanged compared with six weeks after surgery. 
 
Ambulatory blood pressure 
Data on 24h ABP are presented in Table 6. Median 24h SBP at baseline was 
significantly correlated to baseline PTH (r=0.24), serum insulin (r=0.29) and TG 
(r=0.37), p<0.01, and inversely to IGFBP-1 (r=-0.19; P<0.005). 24h SBP decreased in 
both groups. The change in 24h SBP was not correlated to changes in PTH, ionized 
calcium or 25-OH-D (data not shown). Eleven patients, equally distributed between the 
D+ and the D- group, were able to either cease or reduce their antihypertensive 
treatment. Vitamin D supplementation did not give any additive effect. 
 
Body composition 
Total body BMC increased in both D+ and D- (rBMC: D+ 68 g (-16-127), p<0.001; 
D- 56 g (-32-108), p=0.013). The changes in BMC, LBM and fat mass did not correlate 
to the change in either 25-OH-D or Ca2+, but there was an inverse correlation between 
delta PTH and delta BMC (r=-0.30, p=0.002). 
 
4.3.2 Study IV 
Bone mineral density 
BMD at baseline was similar in the D+ and D- groups. After twelve months of study 
medication, median BMD had increased significantly in the lumbar spine, the total hip 
and the femoral neck in both the D+ and the D- group (Table 7). Patients in the D+ 
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group also increased their BMD of the ultra-distal forearm. The increase in BMD did 
not differ either between patients with or without osteoporosis, or between men and 
women (data not shown).  
 
BMD at baseline and the change in BMD did not differ between patients with or 
without vitamin D insufficiency (25-OH-D<50nmol/l). In both groups BMD improved 
in the lumbar spine and hips; the insufficient patients had an increased BMD in the 
ultra-distal forearm as well. No significant additive effect of vitamin D supplementation 
was observed. For patients with insufficient vitamin D levels after 1 year, BMD was 
lower in the lumbar spine, 1/3 proximal forearm and ultra-distal forearm (p<0.05).  
 
The changes in BMD, especially in the hips, were correlated to the baseline 
concentrations of PTH, ionized calcium and bone turnover markers, but not to vitamin 
D (Figure 6). This correlation remained significant when controlling for age, gender, 
smoking, weight and creatinine (r=0.38, p<0.001).  
 
Patients with PTH > 65 ng/l 6±2 weeks after PTX had a greater improvement in BMD 
in the total hip, femoral neck and distal forearm than patients with normalized PTH 
levels. In patients with PTH > 65 ng/l after PTX, BMD increased at all measured sites 
in the D+ group, but not in the forearm (ultra-distal and 1/3 proximal forearm) in the D- 
group, without regard to vitamin D status at baseline. 
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Figure 6 Correlations between delta BMD total hip and baseline PTH, Ca2+ and bone 
turnover markers. 
 
 
Biochemical markers of bone turnover 
In 79 patients, P1NP and βCTx were within the normal range at baseline, while 70 
patients had an increased level of P1NP (n=46), βCTx (n=1) or both (n=23). Patients 
with bone turnover markers above the normal range at baseline had higher PTH, 
ionized calcium and ALP (PTH: 120 (101-152) vs. 105 (84-133), ionized calcium: 1.46 
(1.41-1.51) vs. 1.42 (1.38-1.44), ALP: 1.3 (1.1-1.6) vs. 1.2 (0.9-1.4), p<0.05). 
 
βCTx and P1NP decreased significantly in both groups from baseline to six weeks and 
one year after PTX (Table 5 and 6). βCTx changed most after PTX, while the decrease 
in P1NP was more pronounced after one year. Both bone turnover markers were 
correlated to the change in BMD (Figure 6). There was no correlation between the bone 
turnover markers and 25-OH-D, except for a weak inverse correlation six weeks after 
PTX between 25-OH-D and βCTx (r=-0.21, p<0.05). 
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5 DISCUSSION 
5.1 STUDY I 
Postoperative mortality after parathyroid adenomectomy in Sweden has decreased from 
4.2 % to 0.4 % since 1961, notwithstanding a simultaneous 11-year increase in 
patients’ mean age. Similar postoperative mortality data have been reported167. There 
are several plausible explanations. Measurements of serum calcium became routine in 
the 1970’s and lead to earlier diagnosis and less severe disease at the time of surgery. 
Modern anaesthetic procedure and better postoperative care may also affect the 
postoperative mortality. Better preoperative localization techniques have paved the way 
for focused surgery, even under local anaesthesia. However, in our country, 99% of 
PTX are still performed under general anaesthesia168. Improved medical treatment of a 
number of chronic diseases has made it possible to operate patients despite a certain 
degree of comorbidity. Surgery in the elderly seems to be safe and beneficial169-171. 
 
The dominant cause of death, for all ages and both genders, within the first month and 
the following year after PTX was cardiovascular disease. This is in line with the 30-day 
mortality of other elective surgical procedures, such as groin hernia repair172. Several 
risk factors for cardiovascular disease are overrepresented in pHPT28 and an increased 
mortality in cardiovascular disorders has been demonstrated26,95,96. It may be assumed 
that the duration of the disease is important for the prognosis, since mortality risk has 
been associated with the degree of hypercalcaemia and the weight of the adenoma95. 
 
Postoperative mortality after PTX was higher than for other elective surgical 
procedures, such as inguinal hernia repair, thyroidectomy for benign goitre and 
cataract173-175. After PTX, an increased mortality persists for at least 15 years26.  
 
Hypercalcaemic crisis could also affect mortality rates, since it is associated with a 
significant mortality, especially in patients with extremely high serum calcium 
levels176,177. In a study of 1055 patients who underwent PTX from 1969 to 2004, the 
prevalence of hypercalcaemic crisis was estimated to be 4%176. 
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5.1.1 Strengths and limitations 
The registries used are well validated and the size of the investigated cohort provides 
good statistical power. A limitation is that the cohort does not represent the entire 
pHPT population in Sweden, since the registry does not include either conservatively 
treated patients or patients with multiglandular disease, comprising approximately 15% 
of the pHPT population. Neither are there any data on the degree of hypercalcaemia, 
symptoms, surgical procedure or postoperative serum calcium levels. In a long-term 
follow-up of Swedish patients, 95% had reversed hypercalcaemia after PTX178,179.  
 
 
5.2 STUDY II 
The results in this nested case-control study indicate that factors predictive of prognosis 
and response to therapy did not differ between patients with breast cancer and previous 
surgery for pHPT and matched controls without previous PTX, although none of the 
cases had stage III or IV disease..  
 
PHPT and breast cancer have several characteristics in common. Both mainly affect 
postmenopausal women and have been associated with obesity and increased calcium 
and 25-OH-D levels48-51,57,58,180. The mammary gland has receptors for both calcium181, 
PTH182 and vitamin D 183. A causal relationship between calcium and/or PTH levels 
and breast cancer seems less likely, since unlike cardiovascular mortality, the risk of 
breast cancer remains unchanged at least 15 years after PTX26,27. Neither did Almquist 
et al. find any association between PTH level and breast cancer in a nested case-control 
study of 764 patients with breast cancer48.  
 
Vitamin D deficiency is a factor that could contribute to the aetiology of both breast 
cancer and pHPT. 1,25-(OH)2-D has the ability to inhibit proliferation, invasion and 
angiogenesis and promote differentiation and apoptosis184,185. There is a potential link 
between vitamin D deficiency and both the development and prognosis of breast 
cancer185-187 as well as an aggravated clinical presentation of pHPT and larger 
parathyroid adenomas82,188. Two meta-analyses of serum vitamin D and breast cancer 
risk found an inverse association with 25-OH-D measured after diagnosis of breast 
cancer. However, this could not be confirmed in prospective studies with measurements 
of 25-OH-D years before diagnosis50,51. Neither have studies on a possible association 
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between vitamin D intake and breast cancer risk yielded consistent results. A meta-
analysis of observational studies found a possible positive effect of higher intakes of 
vitamin D189 but a nested case-control study of calcium and vitamin D supplementation 
versus placebo during seven years (mean) did not show any protective effect190. 
However, 57% of the subjects in the placebo arm took personal supplements, and a re-
analysis restricted to the women not taking any extra calcium and/or vitamin D, showed 
a 14-20% decrease in the risk of breast cancer in the calcium and vitamin D arm191. 
Many factors may complicate the interpretation of data on vitamin D status, such as 
age, BMI, liver and kidney function, chronic illness and sun exposure192.  
 
Obesity is another factor associated with both pHPT57,  an increased risk of 
postmenopausal breast cancer180,193 and vitamin D deficiency194. In addition to 
oestrogen, hyperinsulinaemia is suggested to be a contributory risk factor for breast 
cancer in obese postmenopausal women193,195 and is also associated with pHPT19. 
 
 
5.2.1 Strengths and limitations 
The strengths of the study are the use of well-validated registers, including two of the 
most important prognostic factors – tumour size and lymph node involvement. The risk 
of confounding by diagnosis was minimized by excluding cases with a breast cancer 
diagnosis before pHPT. Other strengths are the relatively large number of observations 
with five controls per case and the long follow-up. 
 
The main weakness lies in the scope of the data in the registers. Data on HER-2/neu 
and the cell proliferation marker Ki67 were incomplete. Elston-Ellis tumour grading 
could not be properly analysed because of too many missing data, especially in the 
early period. Neither did the register include any information on risk factors for breast 
cancer, treatment modalities and biochemical data in the register. However, bias 
because of differences in treatment is likely to be negligible, since the compliance with 
the regional and national treatment guidelines is excellent and controls were matched 
for region. Misclassification of controls may affect isolated cases, based on the 
comparatively low incidence of pHPT in the population9. 
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5.3 STUDIES III AND IV 
The major findings in this randomized, double-blind study were that PTX had 
beneficial effects on insulin resistance, blood pressure and bone mineral density. 
However, despite a high prevalence of vitamin D insufficiency (76 % < 50 nmol/l) in 
the cohort, postoperative supplementation with vitamin D had no obviously beneficial 
effect. Preoperative SBP and the increase in BMD correlated with the preoperative 
PTH concentration. 
 
Vitamin D supplementation did lower the level of PTH in the D+ group. At follow-up 
this group had a significantly higher concentration of 25-OH-D, indicating an adequate 
dose of vitamin D. 
 
50 % of the patients had a persistently high concentration of PTH six weeks after PTX. 
The clinical importance of persistent PTH elevation after curative PTH is still an open 
question36. Several factors are probably causally involved. One is the interval after PTX 
and another is secondary hyperparathyroidism due to vitamin D deficiency, which was 
the case in some, but not all patients. High postoperative levels of PTH have been 
associated with larger adenomas and high preoperative PTH, as in the patients in the 
present study, and may be due to an increased need of calcium in the remineralization 
of the bone or to an increased peripheral resistance to PTH 37,38.  
 
The cause and clinical importance of the persistent PTH elevation in nearly 20% of the 
patients more than one year after PTX are more complicated. Not all of them had a low 
vitamin D concentration and only one showed obvious signs of recurrent disease. Our 
results are in line with other long term follow-up studies after PTX36,196,166. 
 
Vitamin D supplementation resulted in a lower PTH concentration at follow-up after 
one year. It cannot be excluded that the higher PTH concentration in the D- group has 
negative effects in the long term. In the general population, PTH in the upper normal 
range has been associated with an increased risk of cardiovascular complications88,89,197, 
increased blood pressure198,199 and decreased insulin sensitivity107,200. Furthermore, a 
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high PTH level in combination with low vitamin D has been associated with an 
increased risk of fractures201.  
Among patients with pHPT, those with low vitamin D levels and a higher PTH 
concentration have also been found to have greater catabolic effects in cortical bone 
and greater anabolic effects in cancellous bone202. 
 
 
5.3.1 Insulin resistance and pHPT 
Available reports on the relationship between pHPT and insulin resistance and the 
effect of PTX are contradictory123,124,128,130. The simultaneous reduction of HOMA-IR, 
glucose, insulin and IGF-I and the increase in IGFBP-1 seen postoperatively and 
remaining at follow-up, support a possible reversibility of the impaired glucose 
metabolism coupled to pHPT. The underlying mechanism is not clear, since both PTH 
and calcium are associated with insulin sensitivity200,203.  
 
In a randomized study on vitamin D supplementation to women with insulin resistance 
and vitamin D deficiency, vitamin D had a positive effect on insulin resistance and 
sensitivity; the optimal vitamin D concentration was ≥ 80 nmol/l204 (von Hurst 2010). 
In the present study, the median 25-OH-D concentration at one year was 76 nmol/l. 
Even so, effects of vitamin D on insulin resistance could not be seen, beyond the 
positive effect of PTX. 
 
5.3.2 Blood pressure and pHPT 
Control of hypertension appears to be crucial for the prevention of cardiovascular 
complications. The Framingham Study has confirmed that the risk of cardiovascular 
complications increases incrementally with blood pressure even within the normal 
range and that SBP is a more important risk factor than DBP205,206. It is also well 
established that 24h ABP is superior to single office measurements in predicting a risk 
of cardiovascular morbidity and mortality119. The available information on 24h ABP in 
pHPT is limited to a few studies, with contradictory results108,117,118,120,121. Recently, 
Luigi et al. compared patients with pHPT to patients with essential hypertension and to 
normal subjects, 30 in each group108. They found a strong correlation between PTH and 
SBP and a high prevalence of the metabolic syndrome in patients with pHPT, with 
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significant improvements after parathyroid surgery. Others have also reported a high 
percentage of alterations in the normal circadian rhythm of 24h ABP in pHPT117,120.  
Our patients had a small but significant decrease in SBP, regardless of vitamin D levels. 
The results may be biased by the high proportion of patients with hypertensive 
medication, but similar findings were obtained in another study with selected patients 
without known cardiovascular risk factors80. A positive effect on blood pressure after 
surgery has been demonstrated among patients with pHPT and hypertension105. 
However, few studies have been able to show any effect of PTX on blood pressure. 
Partially irreversible vascular changes may be a possible explanation122.  
 
The coexistence with other risk factors seems to be important and the combination of 
high PTH, hypertension and insulin resistance could potentiate the risk of 
cardiovascular complications in pHPT. 
 
5.3.3 Bone and pHPT 
Vitamin D supplementation had no obviously beneficial effect on bone recovery after 
PTX. The increase in BMD did not differ either between patients with or without 
vitamin D insufficiency or between patients with or without osteoporosis or between 
genders. Instead, the change in BMD correlated with the preoperative concentrations of 
PTH, ionized calcium and bone turnover markers. This is in accordance with other 
studies146,147,151,207.  
 
The results of the present study are comparable to previously reported effects of 
parathyroid surgery only, confirming the positive effects on BMD in sites rich in 
cancellous bone, such as the lumbar spine and total hip130,150,154,208,209.  
 
Studies using DXA and analyses of iliac crest bone biopsies in patients with pHPT, 
show a reduction of cortical width and cortical bone porosity, while the cancellous bone 
is relatively preserved14,143. Recent studies using HR-pQCT found both trabecular and 
cortical abnormalities, resulting in decreased whole bone and trabecular stiffness145 and 
improvements in the microarchitecture after PTX in both cortical and trabecular 
bone146. The potential for improvements in the microarchitecture and bone strengths 
was related to the baseline levels of PTH and bone turnover markers. These findings 
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are consistent with the strong correlation between rBMD and the baseline 
concentration of PTH and bone turnover markers in our patients. 
 
There is a possibility that vitamin D supplementation has a beneficial effect in certain 
subgroups, for example those with a high PTH level after PTX; they showed a greater 
improvement in BMD and a beneficial effect in the forearm from vitamin D 
supplementation. The entire group with vitamin D supplementation also had a positive 
effect on BMD of the ultra-distal forearm. This raises the question of whether vitamin 
D and/or PTH have differential effects on different skeletal compartments, for example 
weight-bearing and non-weight-bearing skeletal sites41 or stage of maturation of the 
bone cells210. In a Danish study on patients with pHPT, high levels of 1,25(OH)2D were 
inversely correlated to BMD in the distal radius211. 
 
5.3.4 Strengths and limitations 
To the best of my knowledge, this is the first randomized study on vitamin D 
supplementation after PTX in patients with pHPT. The strengths of this interventional 
study are the prospective randomized design, the close and standardized follow-up with 
good compliance and the achievement of adequate vitamin D levels in the D+ group. 
Furthermore, the diagnosis was verified by PTX in all cases and the loss to follow-up 
was 10%. The advantage of a proper randomization is that it could eliminate bias in 
treatment assignment, especially selection bias and confounding. In this study, the 
groups were comparable in all studied parameters except for the 24h ABP, which was 
higher in the D+ group. However, the number of patients with medication for 
hypertension was the same in D- and D+ (n=33 vs 34) and both groups showed the 
same decrease in SBP. This is in accordance with a study on selected patients with 
pHPT but without known cardiovascular risk factors80 and another study with a high 
proportion of patients with hypertension108.  
 
The study was blinded to patients, investigators and assessors to further minimize the 
risk of bias (information bias). 
 
The use of calcium carbonate instead of placebo could be a limitation, since one cannot 
definitely exclude the possibility that the calcium supplementation interfered with the 
results. However, the changes in insulin resistance were detected before the start of 
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study medication and remained stable during the study period and the positive effects 
of PTX on BMD and blood pressure have been reported by others108,130,209.  
 
Another limitation may be the time interval between operation and randomization. It is 
our clinical routine to check biochemical parameters after six weeks and we chose to 
randomize the patients at this time point to ensure that they were cured before starting 
the study medication. In some patients, for example those with significant vitamin D 
deficiency or hungry bone, a shorter interval might have been favourable for the early 
mineralization of the bone. 
 
There is a potential risk of type II error, considering the precision errors of the DXA 
and blood pressure devices and the %CV of the assays of the biochemical parameters. 
The sample size was based on the change in PTH (primary end-point), and could 
therefore be too small to detect differences in secondary end-points. 
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6 CONCLUSIONS 
• Parathyroid adenomectomy is a safe procedure today, even in older patients. 
Chronological age per se is no reason for abstaining from surgical treatment of 
pHPT. 
 
• A history of primary hyperparathyroidism does not seem to affect factors 
predictive of prognosis and response to therapy in women with subsequent 
breast cancer.  
 
• Parathyroid adenomectomy has beneficial effects on insulin resistance, blood 
pressure and bone mineral density. 
 
• Supplementation with vitamin D and calcium after parathyroid adenomectomy 
lowers the levels of parathyroid hormone, but no obviously beneficial effect 
was found on blood pressure, metabolic factors or bone mineral density.  
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7 SAMMANFATTNING PÅ SVENSKA (SWEDISH 
SUMMARY) 
Primär hyperparatyreoidism (pHPT) är en sjukdom där en eller flera av de vanligen 
fyra bisköldkörtlarna producerar för mycket av sitt hormon, parathormon (PTH). Det 
leder till för hög koncentration av kalcium i blodbanan. Sjukdomen medför bl. a. 
urkalkning av skelettet, ökad risk för njursten och hjärt- kärlsjukdomar samt ökad 
dödlighet. Orsaken till sjukdomen är vanligtvis okänd. PHPT drabbar ca. 1% av den 
vuxna befolkningen och är vanligast hos kvinnor efter klimakteriet. Den upptäcks ofta 
genom rutinblodprov. Sjukdomen kan botas med kirurgi, där man tar bort den/de sjuka 
körteln/körtlarna.  
 
Medelåldern i befolkningen ökar och därmed även de patienter med pHPT som blir 
aktuella för opereration. Man får då väga riskerna med en operation mot nyttan. I en 
stor kohortstudie på 14 635 patienter som opererats p.g.a. pHPT under perioden 1961 
till 2004, jämfördes dödligheten inom 30 dagar och 31-365 dagar efter operation med 
dödligheten i hela den svenska befolkningen, standardiserad för ålder kön och 
tidsperiod.   
 
Medelåldern hos patienterna steg från 53 till 64 år, samtidigt som dödligheten inom 30 
dagar efter operation sjönk från 4.2% till 0.4%. Under senare år var en fjärdedel av 
patienterna 75 år och äldre. Den vanligaste dödsorsaken var hjärt- och kärlsjukdom. 
 
Patienter med pHPT har också en ökad risk att drabbas av vissa cancerformer, varav 
bröstcancer är den vanligaste. I en registerstudie jämfördes bröstcancer hos kvinnor 
med och utan tidigare operation p.g.a. pHPT avseende prognostiska faktorer och 
dödlighet. Grupperna skilde sig inte åt avseende tumörstorlek, hormonreceptorstatus, 
lymfkörtelengagemang eller dödlighet i bröstcancer. 
 
En hög andel av patienter med pHPT har brist på D-vitamin, vilket kan förvärra 
sjukdomens komplikationer. Efter botande operation av pHPT återhämtar sig 
bentätheten till viss del. Huruvida riskfaktorerna för hjärt- kärlsjukdom påverkas eller 
ej är inte helt klarlagt. De studier som finns är motstridiga. I avhandlingen undersöks 
om man kan påskynda och/eller förbättra återhämtningen i skelett och metabola 
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faktorer som blodtryck och blodsockerreglering, genom att ge D-vitamintillskott efter 
operationen. Av 150 patienter fick hälften kalcium och D-vitamin och hälften enbart 
kalcium under ett år efter botande operation för pHPT. Själva operationen hade en 
gynnsam effekt på bentäthet, blodtryck och blodsockerreglering men D-vitamin verkar 
inte tillföra någon ytterligare effekt, utom möjligen på bentätheten. D-vitamintillskott 
sänkte nivån av PTH, vilket i sig skulle kunna vara gynnsamt på lång sikt, då PTH åt 
det högre hållet är kopplat till t. ex. ökad risk för frakturer och hjärt- kärlsjukdom. 
 
Sammanfattningsvis har vi sett att prognosen hos patienter med bröstcancer inte verkar 
skilja sig mellan de som har eller inte har haft pHPT. Nuförtiden är operation av primär 
hyperparatyreoidism säker, även hos äldre personer. Ålder i sig bör inte utesluta att 
patienten får genomgå en potentiellt botande behandling av pHPT. Kirurgisk 
behandling av pHPT har en gynnsam effekt på PTH-nivå, bentäthet och 
blodsockerreglering samt till viss del blodtryck. Någon säker vinst av D-vitamintillskott 
efter operation har inte kunnat påvisas, mer än en sänkning av PTH, vilket skulle kunna 
ha positiva effekter i sig. 
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